{"id":826891,"date":"2025-03-18T08:39:32","date_gmt":"2025-03-18T12:39:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/"},"modified":"2025-03-18T08:39:32","modified_gmt":"2025-03-18T12:39:32","slug":"palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/","title":{"rendered":"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025"},"content":{"rendered":"
\n

WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA)\u00a0Palvella Therapeutics, Inc.<\/a>\u00a0(Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025.<\/p>\n

Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update.<\/p>\n

To access the live webcast of the call with slides, please click here<\/a> or visit the “Events & Presentations” section of Palvella\u2019s website. To access the call by phone, please use this registration link<\/a>, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the “Events & Presentations” section of the Company’s website at www.palvellatx.com<\/a>.<\/p>\n

\n About Palvella Therapeutics<\/strong>\n <\/p>\n

Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN\u2122 platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella\u2019s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN\u2122 rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit\u00a0www.palvellatx.com<\/a>\u00a0or follow Palvella on\u00a0LinkedIn<\/a>\u00a0or\u00a0X<\/a>\u00a0(formerly known as Twitter).<\/p>\n

QTORIN\u2122 rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.<\/p>\n

\n Contact\u00a0Information<\/strong>\n <\/p>\n

\n Investors<\/u>
\n
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com<\/a><\/p>\n

\n Media<\/u>
\n
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA)\u00a0Palvella Therapeutics, Inc.\u00a0(Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the “Events & Presentations” section of Palvella\u2019s website. To access the call by phone, please use this registration link, and you … <\/p>\n

Continue reading “Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826891","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPalvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA)\u00a0Palvella Therapeutics, Inc.\u00a0(Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the “Events & Presentations” section of Palvella\u2019s website. To access the call by phone, please use this registration link, and you … Continue reading "Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T12:39:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025\",\"datePublished\":\"2025-03-18T12:39:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/\"},\"wordCount\":348,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/\",\"name\":\"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=\",\"datePublished\":\"2025-03-18T12:39:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/","og_locale":"en_US","og_type":"article","og_title":"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - Market Newsdesk","og_description":"WAYNE, Pa., March 18, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA)\u00a0Palvella Therapeutics, Inc.\u00a0(Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its full year 2024 financial results on Monday, March 31, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Monday, March 31, 2025, to discuss financial results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the “Events & Presentations” section of Palvella\u2019s website. To access the call by phone, please use this registration link, and you … Continue reading \"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T12:39:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025","datePublished":"2025-03-18T12:39:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/"},"wordCount":348,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/","name":"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=","datePublished":"2025-03-18T12:39:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTkyMCM2ODEwMjc4IzIxMjMxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palvella-therapeutics-to-host-full-year-2024-financial-results-conference-call-on-march-31-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826891"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826891\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}